Comparative Pharmacology
Head-to-head clinical analysis: ACCUTANE versus AMNESTEEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCUTANE versus AMNESTEEM.
ACCUTANE vs AMNESTEEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that reduces sebum production, normalizes follicular keratinization, and decreases Propionibacterium acnes growth by binding to nuclear retinoic acid receptors, altering gene expression.
Retinoid that binds to and activates retinoic acid receptors (RARs), thereby normalizing keratinocyte differentiation and reducing sebum production.
Isotretinoin 0.5-1 mg/kg/day orally in 2 divided doses for 15-20 weeks.
0.5-1.0 mg/kg/day orally in 2 divided doses
None Documented
None Documented
Terminal elimination half-life of isotretinoin is 10-20 hours. The half-life of the major metabolite, 4-oxo-isotretinoin, is 11-50 hours. The long half-life of the metabolite may contribute to sustained clinical effects.
Terminal elimination half-life: 10-20 hours (mean 17 hours) in patients with normal renal function; prolonged in severe renal impairment
Renal and biliary: approximately equal amounts of metabolites are excreted in urine and feces. Unchanged drug is not excreted. Major metabolites: 4-oxo-isotretinoin, tretinoin, 4-oxo-tretinoin. Renal excretion of metabolites accounts for ~65-83% of the dose; fecal excretion accounts for the remainder.
Renal (65-83% as unchanged drug and metabolites), fecal (15-35% as metabolites)
Category C
Category C
Retinoid
Retinoid